The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.
Vifor's board said it has agreed to the merger, which also has the backing of the drugmaker's largest shareholder – investment group Patinex AG – which holds a 23.2% stake in the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback